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Abstract
Background: A considerable number of patients with severely elevated LDL-C do not achieve recommended
treatment targets, despite treatment with statins. Adults at high cardiovascular risk with hypercholesterolemia and
LDL-C ≥ 2.59 and ≤ 4.14 mmol/L (N = 250), pretreated with atorvastatin 20 mg were randomized to ezetimibe/
simvastatin 10/40 mg or atorvastatin 40 mg for 6 weeks. The percent change in LDL-C and other lipids was
assessed using a constrained longitudinal data analysis method with terms for treatment, time, time-by-treatment
interaction, stratum, and time-by-stratum interaction. Percentage of subjects achieving LDL-C < 1.81 mmol/L, < 2.00
mmol/L, or < 2.59 mmol/L was assessed using a logistic regression model with terms for treatment and stratum.
Tolerability was assessed.
Results: Switching to ezetimibe/simvastatin resulted in significantly greater changes in LDL-C (-26.81% vs.-11.81%),
total cholesterol (-15.97% vs.-7.73%), non-HDL-C (-22.50% vs.-10.88%), Apo B (-17.23% vs.-9.53%), and Apo A-I (2.56%
vs.-2.69%) vs. doubling the atorvastatin dose (all p ≤ 0.002), but not HDL-C, triglycerides, or hs-CRP. Significantly
more subjects achieved LDL-C < 1.81 mmol/L (29% vs. 5%), < 2.00 mmol/L (38% vs. 9%) or < 2.59 mmol/L (69% vs.
41%) after switching to ezetimibe/simvastatin vs. doubling the atorvastatin dose (all p < 0.001). The overall safety
profile appeared generally comparable between treatment groups.
Conclusions: In high cardiovascular risk subjects with hypercholesterolemia already treated with atorvastatin 20
mg but not at LDL-C < 2.59 mmol/L, switching to combination ezetimibe/simvastatin 10/40 mg provided
significantly greater LDL-C lowering and greater achievement of LDL-C targets compared with doubling the
atorvastatin dose to 40 mg. Both treatments were generally well-tolerated.
Trial registration: Registered at clinicaltrials.gov: NCT00782184
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Despite substantial lipid-lowering with the use of statins,
a considerable number of patients at high cardiovascular
risk and/or with severely elevated low-density lipopro-
tein cholesterol (LDL-C) do not achieve the rigorous
treatment targets recommended by European, Canadian
and US guidelines [1-4]. LDL-C reductions beyond that
achieved by currently used statin therapies are recom-
mended for a considerable number of patients [4-7].
Clinical trial results have demonstrated that combining
ezetimibe with a statin more effectively lowers LDL-C
vs. treatment with either of the individual components
alone [7,8]. In addition, combining ezetimibe with sim-
vastatin has been shown to provide greater cholesterol
lowering vs. doubling the statin dose in patients with
hypercholesterolemia [9], in those at high risk for coron-
ary heart disease (CHD) [10], and in patients with either
diabetes [11,12] or metabolic syndrome [13].
Previous studies included other dose ranges, popula-
tions with type 2 diabetes or metabolic syndrome, or
did not include target attainment as a primary or sec-
ondary endpoint. The objective of this study was to
assess the efficacy and tolerability profile of switching to
ezetimibe/simvastatin 10/40 mg compared with doubling
the baseline atorvastatin dose to 40 mg in high cardio-
vascular risk subjects with primary hypercholesterolemia
and not at LDL-C goal of < 2.59 mmol/L with atorvasta-
tin 20 mg treatment at baseline. This trial assessed per-
cent change from baseline in LDL-C as the primary
endpoint and attainment of LDL-C targets as the sec-
ondary endpoints using ezetimibe added to simvastatin
40 mg compared with atorvastatin 40 mg in a popula-
tion of subjects at high risk for CHD. Other secondary
endpoints included the percent change from baseline in
other lipids, lipid ratios, and high-sensitivity C-reactive
protein (hs-CRP) after the 6-week treatment period.
Methods
This was a randomized, double-blind, active-controlled,
2-arm, multicenter study conducted at 60 sites (11 in
the US; 7 in Malaysia; 6 each in Hungary, Poland, and
Spain; 5 in Romania; 4 each in Costa Rica, Guatemala,
Latvia, and Peru; 2 in Estonia; and 1 in Israel) from
November 2008 to September 2010. The protocol (Pro-
tocol 134) and amendments were reviewed and
approved by an institutional review board. The study
was conducted in conformance with applicable country
or local requirements regarding ethical committee
review, informed consent, and other statutes or regula-
tions regarding the protection of the rights and welfare
of human subjects participating in biomedical research.
All subjects signed informed consent prior to any study
procedures being performed.
Subjects
Eligible subjects were adults 18-79 years of age at high
risk for CHD with primary hypercholesterolemia. For 6
weeks prior to screening, subjects eligible for the run-in
period were currently taking either atorvastatin 20 mg
or another lipid-lowering therapy with potency ≤ ator-
vastatin 20 mg, or were naïve to lipid-lowering therapy
(naïve was defined as not being treated with a statin
and/or ezetimibe). During the 5-week run-in period,
subjects received open label atorvastatin 20 mg and life-
style, diet counseling, and treatment compliance recom-
mendations. All subjects must have been at high risk as
defined by the National Cholesterol Education Program
Adult Treatment Panel (NCEP ATP) III, which included
subjects with CHD, having a CHD risk equivalent medi-
cal condition, and those who had 2+ risk factors that
confer a 10-year risk for CHD > 20% as determined by
the Framingham calculation [3]. Laboratory entry cri-
teria included LDL-C ≥ 100 mg/dL (2.59 mmol/L) and
≤ 160 mg/dL (4.14 mmol/L) at baseline (Visit 2, which
is a treated baseline following the active treatment run-
in period), triglyceride level ≤ 4.0 mmol/L (≤ 350 mg/
dL), liver transaminases (alanine aminotransferase [ALT]
and aspartate aminotransferase [AST]) ≤ 2.0 × upper
limit of normal (ULN) with no active liver disease, and
creatine kinase (CK) levels ≤ 3x ULN. Subjects were
excluded from participating if they were taking simvas-
tatin 80 mg, atorvastatin 40 or 80 mg, or rosuvastatin
10, 20, or 40 mg, or were taking other prescription and/
or over-the-counter-drugs with the potential for signifi-
cant lipid effects (other than study drug) or with poten-
tial drug interactions with the statins. Females who were
pregnant or lactating were also excluded.
Blinding & randomization
The Clinical Biostatistics department of the study spon-
sor generated the randomized allocation schedule for
study treatment assignment. At the end of the run-in
period, eligible subjects were randomized in a 1:1 ratio
to atorvastatin 40 mg or ezetimibe/simvastatin 10/40
mg. To achieve balance across treatment groups, sub-
jects were stratified by their baseline LDL-C values at
randomization (taken at Visit 3): Stratum 1: ≥ 2.59
mmol/L (100 mg/dL) and < 3.36 mmol/L (130 mg/dL)
and Stratum 2: ≥ 3.36 mmol/L (130 mg/dL) and ≤ 4.14
mmol/L (160 mg/dL). Subjects received open label run-
in bottles containing atorvastatin 20 mg. Treatment was
supplied in blinded kits, each containing 2 bottles
labeled A and B. Subjects were instructed to take one
tablet daily from each of the bottles provided. The final
database was not unblinded until medical/scientific
review was performed, protocol violators were identified,
and data had been declared final and complete.
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LDL-C was calculated using the Friedewald method
when triglycerides were < 4.52 mmol/L (400 mg/dL).
The beta quantification ultracentrifugation method was
used if triglycerides reached ≥ 4.52 mmol/L (400 mg/
dL). Total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), hs-CRP, apolipoprotein (Apo) A-I,
Apo B, and triglyceride fasting plasma levels were deter-
mined by a central laboratory. Non-HDL-C, LDL-C/
HDL-C ratio, TC/HDL-C ratio, non-HDL-C/HDL-C
ratio, and Apo B/Apo A-I ratio were calculated using
the laboratory measurements.
Safety measures
Clinical evaluation included physical examinations, vital
signs (blood pressure, weight, height, pulse rate), and
laboratory safety tests. Clinical safety evaluations, includ-
ing serious adverse events (AEs) and discontinuations
due to clinical and/or laboratory AEs, were performed
at Visits 2, 3, 4, and 5. Laboratory safety test evaluations
were performed at Visits 1, 3, and 5 during the study.
Statistical methods
Sample size
Approximately 240 patients were expected to be rando-
mized to ensure that 220 evaluable subjects would be
included in the analysis of the full analysis set (FAS)
population (110 per treatment group). With this enroll-
ment, the study was assumed to have 95% power to
detect a treatment difference of 10% in percent change
from baseline between ezetimibe/simvastatin 10/40 mg
and atorvastatin 40 mg assuming a standard deviation
(SD) of 20% (at significance level = 0.05, 2-sided).
Statistical analysis
Primary and secondary efficacy data were analyzed
based on the FAS population, which included all rando-
mized subjects who had a baseline measurement and
received at least 1 dose of study medication. For the pri-
mary and secondary efficacy endpoints involving percent
change from baseline (except triglycerides and hs-CRP),
between-group differences were analyzed using a con-
strained longitudinal data analysis (LDA) model, includ-
ing both baseline and post-baseline percent change from
baseline measurements as the response variable, and
with terms for treatment, time, the interaction of time-
by-treatment, stratum, and the interaction of time-by-
stratum with a restriction of the same baseline mean
across treatment groups (due to randomization). Due to
the non-normal distribution associated with percent
changes from baseline in triglycerides and hs-CRP, data
were log-transformed. The percentage of subjects reach-
ing LDL-C < 1.81 mmol/L (70 mg/dL), < 2.00 mmol/L
(77 mg/dL) and < 2.59 mmol/L (100 mg/dL),
respectively, was analyzed using a logistic regression
model with terms for treatment and stratum.
There were 1 primary and 3 secondary efficacy
hypotheses. Since there was only 1 primary efficacy end-
point and only 1 primary treatment comparison, no
adjustment for multiplicity was applied for the primary
hypothesis and the treatment comparison was per-
formed at significance level 0.05. Analysis of the second-
ary variables related to secondary hypotheses was
performed if the primary variable was significant at level
0.05. A step-down ordered testing procedure, which
keeps the overall Type I error at level 0.05 if each test is
performed at level 0.05, was performed for the key sec-
ondary variables. Specifically, the primary comparison of
ezetimibe/simvastatin (10/40 mg) versus atorvastatin 40
mg in percent change from baseline in LDL-C was per-
formed first. The tests of the secondary hypotheses were
performed in the following order if the primary end-
point was significant at level 0.05: (1) percentage of sub-
jects reaching LDL-C goal of < 1.81 mmol/L (70 mg/
dL), (2) percentage of subjects reaching LDL-C goal of <
2.00 mmol/L (77 mg/dL), (3) percentage of subjects
reaching LDL-C goal of < 2.59 mmol/L (100 mg/dL).
The ordered testing procedure was to stop at any step
where statistical significance was not achieved.
Safety data
The All Patients as Treated (APaT) population, which
consisted of all randomized subjects who received at
least one dose of study treatment, was used for the ana-
lysis of safety data. Inferential testing provided statistical
significance levels for between-group comparisons on
the following safety parameters: gastrointestinal-related
AEs, gallbladder-related AEs, allergic reaction or rash
AEs, hepatitis-related AEs, elevations in ALT/AST ≥ 3×
ULN, elevations in CK ≥ 10× ULN, elevations in CK ≥
10× ULN with muscle symptoms and elevations in CK
≥ 10× ULN with drug-related muscle symptoms.
Ninety-five percent confidence intervals (CIs) for treat-
ment differences in proportions using Miettinen and
Nurminen were provided for safety parameters includ-
ing: 1 or more AEs, drug-related AEs, serious AEs, dis-
continuations due to an AE, AEs and predefined limits
of change in laboratory safety parameters with incidence
occurring in at least 4 subjects within at least 1 of the
treatment groups. Descriptive statistics were used for all
other AEs and predefined limits of change
Results
The flow of subjects through the study is summarized in
Figure 1. Of the 1124 subjects screened, 874 subjects
were excluded, leaving 250 subjects to be randomized.
There were 120 subjects randomized to the ezetimibe/
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There were a total of 9 discontinuations, which included
4 from the ezetimibe/simvastatin group and 5 from the
atorvastatin group.
Baseline demographics and clinical characteristics
were generally similar between treatment groups (Table
1). The majority of subjects were white (72%) and the
mean age was 59.3 years (standard deviation [SD] =
9.2). Baseline lipids were generally similar between
groups, with baseline mean LDL-C = 3.12 mmol/L (SD
= 0.42) (120.44 mg/dL [SD = 16.04])
After 6 weeks of treatment, ezetimibe/simvastatin 10/
40 mg resulted in significantly greater reductions from
treated baseline in LDL-C levels compared with dou-
bling the dose of atorvastatin to 40 mg (-26.8% vs
-11.8%; p < 0.001 [Figure 2]). The estimated between-
treatment difference was -15.0% (95% confidence inter-
val [CI]: -21.15, -8.84) in favor of ezetimibe/simvastatin
10/40 mg therapy. The greater efficacy of the ezetimibe/
simvastatin 10/40 mg treatment in reducing LDL-C was
consistent across prespecified subgroups (Figure 3). Sig-
nificantly more subjects attained all prespecified LDL-C
targets with ezetimibe/simvastatin 10/40 mg vs atorvas-
tatin 40 mg after 6 weeks of treatment (all p < 0.001;
Figure 4). The percentage of subjects reaching LDL-C <
1.81 mmol/L (70 mg/dL), < 2.00 mmol/L (77 mg/dL)
and < 2.59 mmol/L (100 mg/dL), respectively, was
29.1% vs 4.8% in the ezetimibe/simvastatin 10/40 mg
group vs the atorvastatin 40 mg group; 38.5% vs. 8.7%
in the ezetimibe/simvastatin 10/40 mg group vs the
atorvastatin 40 mg group; and 69.2% vs 41.3% in the
ezetimibe/simvastatin 10/40 mg group vs. the atorvasta-
tin 40 mg group.
In addition to greater reductions in LDL-C, ezetimibe/
simvastatin treatment resulted in significantly greater
reductions in TC (p <0 . 0 0 1 ) ,n o n - H D L - C( p <0 . 0 0 1 ) ,
Apo B (p = 0.002), Apo A-I (p < 0.001), and all lipid
ratios (all p < 0.001; Table 2). There were no significant
differences between treatments in change from baseline
in triglycerides (p =0 . 5 9 3 ) ,H D L - C( p =0 . 2 1 1 ) ,o rh s -
CRP (p = 0.785; Table 2).
The incidence of clinical and laboratory adverse experi-
ences was generally similar between treatment groups
(Table 3). Discontinuations due to AEs were infrequent
and similar between treatments (2 in the atorvastatin
group and 0 in the ezetimibe/simvastatin group). There
were no discontinuations due to serious AEs and 2 discon-
tinuations due to drug-related AEs, both in the atorvasta-
tin 40 mg group. There were 2 serious AEs reported (1 in
each group) and neither was considered related to study
drug. There was no significant difference between ezeti-
mibe/simvastatin and atorvastatin in the percentage of
subjects with gastrointestinal-related, allergic reactions or
rash-related AEs, or hepatitis-related AEs. No gallbladder-
related AEs occurred in the study and there were no sub-
jects with single or consecutive elevations in ALT ≥ 3×
ULN or AST ≥ 3× ULN or with elevation in CK ≥ 10×
ULN. There were no deaths reported.
Discussion
These results demonstrated that compared with dou-
bling the dose of atorvastatin to 40 mg, switching to the
combination ezetimibe/simvastatin 10/40 mg resulted in
significantly greater reductions in LDL-C levels and
greater achievement of prespecified LDL-C targets in
subjects with primary hypercholesterolemia at high risk
Screened
n=1124
Patients randomized to drug
n=250
Assigned to EZ/Simva 10/40
n=120
Discontinued              
  Adverse event  
  Protocol violation    
  Withdrew consent    
 n=4
 n=1
 n=0
 n=3
Not randomized      
  Inclusion/exclusion criteria 
  Adverse event 
  Lost to follow-up 
  Protocol violation 
  Withdrew consent 
  Other 
N=874
 n=811
 n=11     
 n=8     
 n=1    
 n=42  
 n=1     
Completed study                              
n=116
Assigned to A40 mg  
n=130
Discontinued              
  Adverse event
  Protocol violation    
  Withdrew consent    
 n=5
 n=2
 n=1
 n=2
Completed study                              
n=125
Figure 1 Patient flow through the study.
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(100 mg/dL) with atorvastatin 20 mg. In addition, TC,
non-HDL-C, Apo B, and all lipid ratios were reduced
while Apo A-I was increased significantly more with
combination treatment compared with atorvastatin
monotherapy. The safety and tolerability profiles were
generally similar for both treatment groups.
It has been established that adding ezetimibe to statin
monotherapy results in greater reductions in LDL-C and
other lipids compared with statin monotherapy, even when
existing statin therapy is doubled [14]. The mean LDL-C
reduction observed in the current trial was consistent with
expectations for the combination treatment, which is an
approximately 15% greater reduction vs doubling the statin.
In previous studies, mean reductions in LDL-C of at least
15% beyond that seen with a comparable or greater ator-
vastatin dose has been observed with the addition of ezeti-
mibe to a statin (i.e., atorvastatin 20 mg plus ezetimibe 10
mg vs atorvastatin 40 mg [15]; atorvastatin 40 mg plus eze-
timibe 10 mg vs atorvastatin 80 mg [16]; or ezetimibe/sim-
vastatin 10/40 mg vs simvastatin 40 mg [7]). In other
studies, although still significantly greater, the magnitude
of difference between treatments has been smaller. For
example, in a study of subjects with metabolic syndrome,
Table 1 Baseline demographics and clinical characteristics
EZ/Simva 10/40 mg
n (%)
Atorvastatin 40 mg
n (%)
Total
N = 120 N = 130 N = 250
Male 63 (52.5) 65 (50.0) 128 (51.2)
Mean age (SD) 58.9 (10.0) 59.7 (8.4) 59.3 (9.2)
Age ≥ 65 years 36 (30.0) 36 (27.7) 72 (28.8)
Race
White 89 (74.2) 90 (69.2) 179 (71.6)
Asian 21 (17.5) 24 (18.5) 45 (18)
Multi-Racial 10 (8.3) 14 (10.8) 24 (9.6)
American Indian or Alaska
Native
0 1 (0.8) 1 (0.4)
Black or African American 0 1 (0.8) 1 (0.4)
Ethnicity–Hispanic or Latino 25 (20.8) 29 (22.3) 54 (21.6)
Baseline LDL-C Stratum
Stratum 1: ≥ 2.59 mmol/L (100 mg/dL) to < 3.36 mmol/L (130 mg/dL) 81 (67.5) 97 (74.6) 178 (71.2)
Stratum 2: ≥ 3.36 mmol/L (130 mg/dL) to < 4.14 mmol/L (160 mg/dL) 39 (32.5) 33 (25.4) 72 (28.8)
BMI ≥ 30 kg/m
2 43 (37.1) 41 (32.3) 84 (34.6)
History of Diabetes 42 (35.0) 45 (34.6) 87 (34.8)
Clinical Characteristics, mean (SD)
LDL-C, mmol/L
mg/dL
3.16 (0.43)
122.00 (16.5)
3.08 (0.40)
119.01 (15.52)
3.12 (0.42)
120.44 (16.04)
Total Cholesterol, mmol/L
mg/dL
5.25 (0.55)
202.54 (21.1)
5.14 (0.60)
198.60 (23.11)
5.19 (0.59)
200.49 (22.21)
Triglycerides*, mmol/L
mg/dL
1.53 (0.76)
135.00 (66.98)
1.49 (0.76)
131.50 (66.98)
1.49 (0.76)
132.00 (66.98)
HDL-C, mmol/L
mg/dL
1.33 (0.33)
51.54 (12.87)
1.33 (0.35)
51.18 (13.28)
1.33 (0.34)
51.36 (13.06)
non-HDL-C, mmol/L
mg/dL
3.91 (0.51)
151.00 (19.56)
3.82 (0.51)
147.42 (19.68)
3.86 (0.51)
149.14 (19.67)
Apo B, g/L
(mg/dL)
1.20 (0.16)
119.87 (16.06)
1.17 (0.16)
117.32 (15.83)
1.19 (0.16)
118.54 (15.96)
Apo A-I, g/L
(mg/dL)
1.15 (0.25)
155.15 (24.78)
1.58 (0.28)
157.69 (28.28)
1.60 (0.27)
156.47 (26.63)
LDL-C/HDL-C 2.50 (0.64) 2.46 (0.65) 2.48 (0.64)
Total C/HDL-C 4.12 (0.89) 4.07 (0.91) 4.09 (0.9)
non-HDL-C/HDL-C 3.12 (0.89) 3.07 (0.91) 3.09 (0.90)
Apo B/Apo A-I 0.80 (0.17) 0.77 (0.18) 0.78 (0.18)
hs-CRP*, mg/L 2.15 (2.7) 2.10 (2.7) 2.10 (2.7)
Apo, apolipoprotein; BMI, body mass index; EZ, ezetimibe; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-
density lipoprotein cholesterol; SD, standard deviation; simva, simvastatin
*Values are median and robust SD, calculated for triglycerides and hs-CRP as: interquartile range (IQR)/1.075, where IQR = 3rd quartile minus 1st quartile
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mibe/simvastatin 10/40 mg compared with atorvastatin 40
mg [13]. And in the Vytorin Versus Atorvastatin (VYVA)
study, which assessed subjects with hypercholesterolemia
and established CHD or CHD risk equivalent, ezetimibe/
simvastatin 10/40 mg resulted in a 9% greater decrease in
LDL-C compared with atorvastatin 40 mg [17].
This variation between studies could be due to differ-
ences in study design or subject population; however,
these differences may be mathematical in nature. The
current study, as well as the others that show the larger
m a g n i t u d eo fd i f f e r e n c eb e t ween treatments, included
subjects with a 5- or 6-week treatment run-in period (or
a treated baseline), while the studies with the smaller
magnitudes of difference between treatments had wash-
out periods or enrolled subjects who were naïve to
lipid-lowering treatment. In the former studies (without
washout) the baseline LDL-C level values were deter-
mined after statin therapy and the percent reductions
may reflect the percent additional reduction using a lar-
ger denominator. In contrast, subjects with baseline
LDL-C level values prior to statin therapy would poten-
tially describe a smaller LDL-C reduction, although the
actual LDL-C lowering was actually the same. Interest-
ingly, in a post hoc analysis that compared LDL-C low-
ering with ezetimibe/simvastatin 10/20 mg with
rosuvastatin 10 mg in subjects stratified by statin
potency/dose prior to randomization, the subjects taking
the higher potency/dose statins prior to switch experi-
enced a greater magnitude of effect when switching to
ezetimibe/simvastatin compared with rosuvastatin
monotherapy; and more subjects achieved suggested
therapeutic targets [18].
The results of this trial are also consistent with those
of other trials in which significantly more subjects who
switched from atorvastatin monotherapy (on which sug-
gested LDL-C targets were not achieved) to combination
ezetimibe/simvastatin attained individual LDL-C targets
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Results of trials with placebo run-in were also consistent
with the current study and this was true even in popula-
tions of metabolic syndrome subjects [13,20]. In one
study of subjects with type 2 diabetes, numerically more
subjects achieved LDL-C < 2.59 mmol/L with ezetimibe/
simvastatin 10/40 mg vs atorvastatin 40 mg; however,
the difference was not significant between treatment
groups (93.4% vs 89%, p < 0.07) [12].
Conclusion
Both treatment regimens were generally well-tolerated
with very few discontinuations. There were no reports
of elevations in liver enzymes, which was consistent
with expectations based on the results of previous trials.
These results should be interpreted with caution since
the study was not powered to detect very rare AEs. In
conclusion, switching to combination ezetimibe/simvas-
tatin 10/40 mg provides a generally well-tolerated lipid-
lowering therapy for high cardiovascular risk subjects
with hypercholesterolemia previously treated with ator-
vastatin 20 mg but not attaining LDL-C < 2.59 mmol/L.
Table 2 Percent change from baseline in lipids, lipoproteins, lipid and apolipoprotein ratios and hs-CRP after 6 weeks
of treatment (Full Analysis Set population)
Final absolute lipid
value
LS mean% change
EZ/Simva
10/40 mg
Atorvastatin
40 mg
EZ/Simva 10/40
mg
Atorvastatin 40
mg
Between-treatment
difference*
p-
value
LDL-C, mmol/L (mg/dL) 2.32
(89.75)
2.79
(107.81)
-26.81 -11.81 -15.00 < 0.001
Total cholesterol, mmol/L (mg/
dL)
4.45
(171.67)
4.84
(186.83)
-15.97 -7.73 -8.24 < 0.001
Triglycerides
†‡, mmol/L (mg/dL) 1.40
(124.00)
1.34
(119.00)
-5.41 -7.54 2.13 0.593
HDL-C, mmol/L (mg/dL) 1.39
(53.54)
1.35
(51.94)
5.37 2.89 2.48 0.211
Non-HDL-C, mmol/L (mg/dL) 3.06
(118.13)
3.49
(134.89)
-20. 50 -10.88 -11.62 < 0.001
Apo B, g/L (mg/dL) 1.00
(99.72)
1.08
(108.52)
-17.23 -9.53 -7.69 0.002
Apo A-I, g/L (mg/dL) 1.58
(158.71)
1.51
(151.14)
2.56 -2.69 5.25 < 0.001
LDL-C/HDL-C 1.77 2.20 -28.77 -12.66 -16.1 < 0.001
Total C/HDL-C 3.35 3.77 -18.63 -8.60 -10.02 < 0.001
non-HDL-C/HDL-C 2.35 2.77 -24.41 -11.20 -13.21 < 0.001
Apo B/Apo A-I 0.65 0.73 -18.59 -5.67 -12.91 < 0.001
hs-CRP
†‡, mg/L 1.70 1.80 -6.18 -8.86 2.68 0.785
Apo, apolipoprotein; BMI, body mass index; EZ, ezetimibe; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-
density lipoprotein cholesterol; LS, least squares; simva, simvastatin
*EZ/Simva (10/40 mg) - Atorvastatin 40 mg based on the least squares mean from a constrained LDA model with terms for treatment, time, time-by-treatment
interaction, stratum and time-by-stratum interactions
†Final absolute values are medians
‡Data were transformed by the natural logarithm; the difference in least squares means was based on the difference in the back transformed model-based least
squares means and the associated confidence interval was calculated using the delta method. Geometric mean percent changes from baseline levels were
calculated based on back-transformation via exponentiation of the model-based least squares means and expressed as (geometric mean - 1) multiplied by 100
Table 3 Summary of safety data (All Patients as Treated
population)
EZ/Simva
10/40 mg
N = 119
n (%)
Atorvastatin
40 mg
N = 130
n (%)
≥ 1AE 11 (9.2) 18 (13.8)
Drug-related* AEs 2 (1.7) 3 (2.3)
Serious AEs 1 (0.8) 1 (0.8)
Discontinuations
†
due to an AE 0 2 (1.5)
due to a drug-related AEs 0 2 (1.5)
Gallbladder-related AEs 0 0
Gastrointestinal-related AEs 1 (0.8) 5 (3.8)
Hepatitis-related AEs 1 (0.8) 0
Allergic reaction or rash 0 2 (1.5)
ALT ≥ 3× ULN or AST ≥ 3× ULN 0 0
Creatinine kinase ≥ 10× ULN 0 0
*Determined by the investigator to be related to study drug
†Study medication withdrawn
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; EZ, ezetimibe; simva, simvastatin; ULN, upper limit of
normal
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AE: Adverse event; ALT: Alanine aminotransferase; AST: Aspartate
aminotransferase; APaT: All patients as treated; Apo: Apolipoprotein; CHD:
Coronary heart disease; FAS: Full analysis set; HDL-C: High-density lipoprotein
cholesterol; hs-CRP: High-sensitivity C-reactive protein; LDA: Longitudinal
data analysis; LDL-C: Low-density lipoprotein cholesterol; NCEP ATP III:
National Cholesterol Education Program Adult Treatment Panel III; SD:
Standard deviation.
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